Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CorMedix Inc.

Get SEC filing alerts via email and in your feed for CorMedix Inc.

CRMD

CorMedix Inc.

About CorMedix Inc.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases. Its flagship product, DefenCath, is an FDA-approved antimicrobial catheter lock solution designed to reduce bloodstream infections in dialysis patients. The company targets healthcare providers and hospitals in the U.S., leveraging reimbursement mechanisms and proprietary patents to address significant unmet medical needs in infection prevention and vascular access management.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CorMedix Inc.

1
1
CorMedix Inc. CorMedix Reports 226% Revenue Growth to $127.4 Million in Latest Quarter

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
CorMedix Inc. CorMedix Inc. Reports $163.1 Million Net Income and $311.7 Million Revenue in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
CorMedix Inc. CorMedix Reports 810% Revenue Growth to $104.3 Million in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CorMedix Inc. CorMedix Reports 4,829% Revenue Growth to $39.7 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CorMedix Inc. CorMedix Reports $39.1 Million in Net Sales for Q1 2025, Driven by DefenCath Launch

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CorMedix Inc. CorMedix Reports $43.5 Million Revenue from DefenCath Launch in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
CorMedix Inc. CorMedix Reports Q3 2024 Financial Results, Net Sales Reach $11.5 Million Following DefenCath Launch

Via official filing (AI summary) | over 1 year ago | 0 comments